ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020

TORONTO and CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today that data supporting its Alzheimer’s disease program targeting neurotoxic tau has been accepted for presentation at Tau2020 Global Conference, an international conference sponsored by the Alzheimer’s Association, Rainwater Foundation and CurePSP. ProMIS will present data showing the ability of its novel antibody candidates to bind and neutralize the seeding activity of toxic tau species, which—along with the protein amyloid-beta—are considered the most promising targets for potential Alzheimer’s disease (AD) therapy.

ProMIS Chief Development Officer Dr. Johanne Kaplan will present the poster, “Selective Targeting of Pathogenic Tau Aggregates with Rationally Designed Antibodies,” as well as a short Lightning Round oral presentation on the first day of the conference, Wednesday, February 12, from 1:45-2:45. The antibodies were generated using ProMIS’ proprietary drug discovery and development platform. The tau antibodies join ProMIS’ lead candidate for AD, PMN310, which targets the toxic oligomer of amyloid beta (AßO), giving ProMIS a pipeline that offers a critical “one-two punch” for potential Alzheimer’s disease therapies.

“Published data from the team led by Nobel Laureate Stanley B. Prusiner M.D., show that Alzheimer’s disease is driven by self-propagating prion-like aggregates of amyloid and tau,” said Dr. Johanne Kaplan, chief development officer of ProMIS Neurosciences. “We created ProMIS to discover and advance new antibody candidates that can selectively target the toxic forms of misfolded proteins, including amyloid and tau, for potential therapies for a range of neurodegenerative diseases. We’re pleased to share our findings for tau with the larger community and to have our data recognized by such an accomplished program committee.”

ProMIS Neurosciences’ drug discovery and development platform produces antibody candidates that meet a key success factor for an AD therapy: the ability to selectively target the toxic form of a misfolded protein, while sparing its normal, physiologically important form. This continues to challenge Alzheimer’s drug development, evidenced most recently by aducanumab’s limited selectivity for AßOs: in the phase 3 EMERGE trial, aducanumab’s off-target binding to plaque caused adverse and dose-limiting ARIA-E (brain swelling) in 35% of participants. ProMIS’ platform not only generates high-quality antibody candidates with precision selectivity for only the toxic species, it also delivers powerful, confirmed candidates in months versus years. Used in combination with new biomarkers for AD, it gives researchers a unique opportunity to dramatically improve the success and speed of drug development efforts.

Tau2020 will take place February 12-13 in at the Marriott Marquis in Washington, D.C. To learn more about AD therapy development efforts, listen to the podcast, Saving Minds, at iTunes or Spotify.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For media inquiries, please contact:
Shanti Skiffington
[email protected]
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.